Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
6 Μαρ 2024 · Treatment-related adverse events were more common in the islatravir plus lenacapavir group (17.3% vs 5.8%), but all were mild to moderate. The most common side effects in this group were dry mouth and nausea. Two people discontinued the drugs due to adverse events unrelated to treatment.
21 Ιουν 2023 · Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype...
18 Νοε 2021 · Thousands of people with HIV will now be offered a new long-acting injection to manage their condition if they would prefer to stop taking daily pills.
31 Ιουλ 2024 · The following table lists HIV medicines recommended for the treatment of HIV infection in the United States, based on the U.S. Department of Health and Human Services (HHS) HIV and AIDS medical practice guidelines. All of these drugs are approved by the U.S. Food and Drug Administration (FDA).
Side effects occurring more frequently in participants who received Apretude compared to participants who received Truvada in either trial include injection site reactions, headache, pyrexia...
9 Νοε 2023 · Several open-label studies have evaluated different regimens containing INSTIs in conjunction with nucleoside reverse transcriptase inhibitors for PEP. Raltegravir-based regimens have been generally well tolerated with mild side-effects, the most notable being musculoskeletal symptoms.
